Sanofi and Regeneron have announced that EU regulators have agreed to review Dupixent for asthma and cemiplimab for advanced cutaneous squamous cell carcinoma. The French pharmaceutical company is seeking approval for Dupixent as an supplementary maintenance treatment in certain adults and adolescents, aged 12 years old and higher, with inadequately controlled moderate-to-severe asthma. The drug
Thyroid cancer patients in the UK could potentially lose access to Ipsen’s Cometriq and Sanofi Genzyme’s Caprelsa via the Cancer Drugs Fund due to NICE rejecting funding for their use. The cost regulators have published draft guidelines rejecting their routine commissioning on the NHS in England and Wales to treat unremovable, locally advanced or metastatic
NICE has reversed its rejection of Sanofi’s Praluent (alirocumab) after the manufacturer agreed to a patient access scheme for the new cholesterol-lowering drug. The scheme includes an undisclosed discount to the NHS and allows NICE to back Praluent and Amgen’s rival Repatha (evolucumab), which had already been discounted in the new final draft guidance.
European regulators have approved Sanofi Pasteur MSD’s cervical cancer vaccine, Gardasil, for the prevention of anal cancer. The European Commission granted marketing authorisation to Gardasil to be used in the prevention of anal precancerous lesions and anal cancers causally related to certain oncogenic human papillomavirus types in both males and females. Roughly 6,800 patients are
European regulators have approved Novo Nordisk’s Tresiba and Ryzodeg, which Novo hopes will challenge Sanofi’s Lantus, the largest selling insulin product globally. The European Commission have granted marketing authorisations for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes in adults.
Sanofi have revealed details regarding their intended job cuts in France which are expected to affect 900 people, and currently appear to be a lot lower than the numbers that had been rumoured. The Paris-based organisation has announced “a project for the adaptation of its activities in France through 2015.” They now plan to begin
With Sanofi expected to be near to announcing the number of planned job losses in France, and worker protests increasing, the Paris-headquartered organisation have received unexpected support from a French government minister. In July this year, Sanofi announced that they planned to cut jobs at two French sites with the aim to protect the organisation’s
Sanofi and Regeneron have announced varied fortunes for their cancer drug Zaltrap, with the drug gaining a quick evaluation in the USA for colorectal cancer, but failing in a late-stage prostate cancer clinical trial. Sanofi announced today that the US Food and Drug Administration (FDA) has granted priority review of the Biologics License Application for
Sanofi yesterday presented new data which they say supports the safety profile of their blockbuster drug, Lantus, hours after dismissing claims from a study that using the diabetes treatment more than doubled the risk of developing cancer. The French giant unveiled new meta-analysis data at the World Diabetes Congress in Dubai, which they say adds
Sanofi and their subsidiary Genzyme announced the publication of their pivotal Phase III TEMSO (Teriflunomide Multiple Sclerosis Oral) study with investigational once-daily oral medication teriflunomide in The New England Journal of Medicine (NEJM). The results showed that teriflunomide, at the 14mg dosage, significantly reduced the yearly relapse rate, reduced disability progressions and improved numerous magnetic